RNA technology Archives

News and Trends 6 Sep 2017

MSD Offers €464M to Buy German Biotech Fighting Cancer with RNA

MSD is back in the RNA field with the acquisition of Rigontec, a German biotech harnessing RNA interference to make the immune system attack cancer cells. After selling selling Sirna Therapeutics three years ago for almost a tenth of the acquisition price, it seemed like MSD was out of the RNA field. However, the big […]

September 6, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 10 Jul 2017

Sanofi and US Partner Launch Phase III Trial in Hemophilia with RNAi

Alnylam and its partner Sanofi are starting a Phase III program to enter its RNAi drug fitusiran in the competitive hemophilia market. Sanofi and its partner Alnylam have announced the start of a Phase III program that seeks to recruit 250 patients to test its RNAi drug fitusiran in patients with both hemophilia A and […]

July 10, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 May 2017

German Biotech Raises €15M to Treat Heart Failure with Non-coding RNA

Cardior Pharmaceuticals will use the funds to develop an innovative technology based on non-coding RNAs involved in cardiac remodeling. Founded less than a year ago, Cardior Pharmaceuticals is dedicated to developing a novel technology to predict and treat heart failure. In such a short timeframe, the German biotech has managed to attract some of the best […]

May 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Jan 2017

RNA Spray fights Viruses and could Sidestep problems with GMOs

RNA and clay could be the future of crop protection and manipulation of plants’ traits. Researchers have managed to use these ingredients to create a spray capable of “vaccinating” plants, teaching them to recognize the genetic material of viruses. RNA-based therapies may have suffered a recent blow in the clinic this week, but when it comes […]

January 13, 2017 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 5 Jan 2017

Shire sells its RNA platform to a US-based Biotech

Shire has sold its RNA therapy program to a smaller biotech that wants to accelerate the development of products from the platform. The Irish drug giant Shire is giving its MRT program, which includes two mRNA platforms and 12 employees, to US-based RaNA Therapeutics. In exchange, Shire will receive an undisclosed share of equity in the biotech as well […]

January 5, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2016

RNAi Therapy is Back: Sanofi is firmly on board to treat Hemophilia

Sanofi Genzyme is offering Alnylam up to €93M ($100M) to co-develop and launch a revolutionary RNAi therapy for hemophilia. But is RNAi really such a good investment? Sanofi Genzyme signed a deal with Alnylam back in 2014 to develop RNAi therapies. Now, despite the general discouragement in RNAi technology, Sanofi has decided to go ahead and […]

November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2016

CRISPR meets RNAi: a whole new Targeted Therapy

Silence Therapeutics just announced preclinical data for a novel CRISPR therapy targeted to the liver using its RNAi delivery expertise. How does it plan to find a space in this challenging and competitive field? Based on the UK’s golden triangle, Silence Therapeutics develops RNAi therapies to treat cancer. Now, it will be applying its targeted RNA delivery […]

November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Sep 2016

Genfit’s Non-Invasive Diagnostic could unlock the NASH Market

Genfit reinforced its leading place in the race to find a cure for NASH when it announced this morning the launch of a program to validate their new diagnostic tool. Genfit is already leading in the development of a cure for Non-Alcoholic Stato-Hepatitis (NASH) with its candidate, Elafibranor, which is in Phase III trials. Now, the French €600M biopharma has […]

September 20, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Sep 2016

“This 30M Series A will help us bring RNA Therapeutics to Immuno-Oncology”

Rigontec is taking a totally new RNA-based approach to immuno-oncology via the RIG-I receptors. The company extended its Series A fundraising to a third round, and some of the top European VC’s doubled its cash pile to almost €30M. Since launching in early 2014, Munich-based Rigontec has broken with traditional immuno-oncology and pioneered a new RNA avenue […]

September 6, 2016 - 4 minutesmins - By Evelyn Warner

vaccination gates foundation vaccine delivery

News and Trends 10 Jun 2016

Gates Foundation is funding EU Biotech to make Vaccines more affordable

Batavia Biosciences has won a €3.3M grant from the Gates Foundation, to fund new research in making cell culture cheaper – and drive down the price of some key vaccines. Within its goal of pushing science forward and bringing to developing countries, the Gates Foundation has outlined vaccine delivery as a key part of its strategy. […]

June 10, 2016 - 3 minutesmins - By Denise Neves Gameiro

MiNa therapeutics rna liver disease biotech

News and Trends 2 Jun 2016

RNA therapy starts first-of-a-kind trial to treat Liver Cancer

MiNA Therapeutics is launching the first saRNA human trial of its kind – OUTREACH for patients with severe liver cancer. MiNA Therapeutics is a London based RNA specialist, developing RNA activation therapeutics that restore normal function to patients’ cells with an initial focus on severe liver cancer. The study is the first-in-human trial of a small activating RNA […]

June 2, 2016 - 2 minutesmins - By Dani Bancroft

spark therapeutics genable gene therapy blindness pigmentosa rhonova

News and Trends 8 Mar 2016

Irish Gene Therapy for Blindness is Acquired by US Leader in the Field

Spark Therapeutics (US) has paid over €13.5M for Genable Technologies (Ireland) and its gene therapy for a degenerative eye disease which progresses to blindness. Spark Therapeutics is one of the players in the re-emerging field of Gene Therapy (which is already establishing records like the most expensive drug). It focuses on debilitating genetic diseases, like inherited […]

March 8, 2016 - 3 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us